Daewon Pharmaceutical Co. Ltd. (003220) — Cash Flow-to-Debt Ratio
Daewon Pharmaceutical Co. Ltd. (003220) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of ₩9.21 Billion could theoretically repay 0% of its total liabilities (₩325.01 Billion) in one year. Check Daewon Pharmaceutical Co. Ltd. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daewon Pharmaceutical Co. Ltd. Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Daewon Pharmaceutical Co. Ltd. across 15 annual periods. See 003220 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Daewon Pharmaceutical Co. Ltd. (2011–2025)
Year-by-year debt coverage analysis for Daewon Pharmaceutical Co. Ltd.. For the full cash flow conversion analysis, see Daewon Pharmaceutical Co. Ltd. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | ₩42.31 Billion | ₩339.07 Billion | ▲ +24.2% |
| 2024 | 0.10x | ₩30.04 Billion | ₩298.81 Billion | ▼ -52.6% |
| 2023 | 0.21x | ₩51.73 Billion | ₩243.73 Billion | ▲ +30.4% |
| 2022 | 0.16x | ₩33.33 Billion | ₩204.78 Billion | ▲ +53.3% |
| 2021 | 0.11x | ₩22.41 Billion | ₩211.18 Billion | ▼ -47.9% |
| 2020 | 0.20x | ₩24.95 Billion | ₩122.44 Billion | ▼ -18.9% |
| 2019 | 0.25x | ₩30.97 Billion | ₩123.32 Billion | ▼ -42.1% |
| 2018 | 0.43x | ₩40.03 Billion | ₩92.24 Billion | ▲ +501.1% |
| 2017 | 0.07x | ₩4.27 Billion | ₩59.07 Billion | ▼ -81.7% |
| 2016 | 0.39x | ₩20.79 Billion | ₩52.67 Billion | ▼ -29.5% |
| 2015 | 0.56x | ₩25.82 Billion | ₩46.09 Billion | ▲ +48.0% |
| 2014 | 0.38x | ₩17.45 Billion | ₩46.11 Billion | ▲ +13.3% |
| 2013 | 0.33x | ₩12.32 Billion | ₩36.89 Billion | ▼ -17.4% |
| 2012 | 0.40x | ₩13.83 Billion | ₩34.20 Billion | ▼ -17.8% |
| 2011 | 0.49x | ₩17.93 Billion | ₩36.47 Billion | — |